NCT01955681|Completed
A Retrospective, Non-interventional, Multicenter, Observational Chart Review Study to Explore the Clinical Benefits of Retreatment With TKI in the Real World.
SEQUENCE
Loading search results
SEQUENCE
Sponsor study identifier
observational
200
1 country
6
Study Start
December 2013
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
August 2014
Actual (reported)Study Completion
August 2014
Actual (reported)This is a retrospective, non-interventional, multicenter, observational chart review study to explore the clinical benefits of retreatment with TKI in the real world.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
August 2014
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
September 30, 2013
Actual (reported)October 7, 2013
Actual (reported)December 2013
Date type not reportedThis date has not been verified as actual or estimated.
August 2014
Actual (reported)August 2014
Actual (reported)The treatment duration of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor re-administration
The median duration of re-administration of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor will be summarized by days or months, if applicable. The range of this treatment duration will also be presented. All analyses will be performed on all eligible patients in this study.
From the start of re-administration of EGFR-TKI to data cut-off date, assessed approximately up to 6 months.
Assessment of progression-free survival for initial, second EGFR-TKI treatment and chemotherapy between two Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor treatments.
From the start of administration of EGFR-TKI to data cut-off date, assessed approximately up to 6 months.
Assessment of overall survival for initial, second EGFR-TKI treatment and chemotherapy between two Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor treatments.
From the start of administration of EGFR-TKI to data cut-off date, assessed approximately up to 6 months.
Assessment of response rate for initial, second EGFR-TKI treatment and chemotherapy between two Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor treatments.
From the start of administration of EGFR-TKI to data cut-off date, assessed approximately up to 6 months.
Assessment of disease control rate for initial, second EGFR-TKI treatment and chemotherapy between two Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor treatments.
From the start of administration of EGFR-TKI to data cut-off date, assessed approximately up to 6 months.
Record treatment duration in the initial EGFR-TKI therapy and first time chemotherapy.
Patients with locally advanced or metastatic Epidermal Growth Factor Receptor mutated Non-small-cell Lung Cancer who Previously Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-line therapy and chemotherapy as second-line Therapy - SEQUENCE study
Chiayi City, Taiwan
Kaohsiung City, Taiwan
Taichung, Taiwan
Research Site
Taipei, Taiwan
Taipei, Taiwan
Taoyuan, Taiwan
Yuh-Min Chen
Taipei Veterans General Hospital, Taiwan
Gee-Chen Chang
Veterans General Hospital -Taichung
Chong-Jen Yu
National Taiwan University Hospital
Cheng-Ta Yang
Chang Gung Memorial Hospital
First Submitted
September 30, 2013
First Posted
October 7, 2013
Study Start
December 2013
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
August 2014
Actual (reported)Between the initial EGFR-TKI therapy and first time chemotherapy.
Contact the study team to confirm eligibility.
Te-Chun Hsia
China Medical University Hospital
Meng-Chih Lin
Chang-Gung Memorial Hospital Kaohsiung
Ying-Huang Tsai
Chang Gung Memorial Hospital
Study Completion
August 2014
Actual (reported)Last Updated
November 4, 2015
Record last verified: 2015-11
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: